Pulmonary Arterial Hypertension Market | USD 13.92 Billion by 2034
The pulmonary arterial hypertension market size was exhibited at USD 8.15 billion in 2024 and is projected to hit around USD 13.92 billion by 2034, growing at a CAGR of 5.5% during the forecast period 2024 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 8.60 Billion |
| Market Size by 2034 | USD 13.92 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 5.5% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Drug Class, Type, Route Of Administration, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America, Europe, Asia Pacific, Latin America, MEA |
| Key Companies Profiled | United Therapeutics Corporation; Bayer; Gilead Sciences, Inc.; Johnson & Johnson; Viatris Inc.; GlaxoSmithKline; Sandoz Inc. (Novartis); Lupin Pharmaceuticals, Inc.; Sun Pharmaceutical Industries, Inc.; Teva Pharmaceuticals Inc. |
The growth of market is majorly attributed to increasing support from government & healthcare authorities for new drug development, rising prevalence of pulmonary arterial hypertension, and favorable reimbursement policies. In addition, substantial research and development activities in field of pulmonary arterial hypertension are also projected to have positive impact on the market growth. For instance, in December 2024, a group of researchers form Cedars-Sinai revealed that unique-cell based approach is well suited for treatment of pulmonary arterial hypertension. Currently, the study in phase I of clinical trials.
Government support for drug development in the field of Pulmonary Arterial Hypertension (PAH) plays a crucial role in advancing research and ensuring the availability of effective treatments. PAH is a rare but severe condition characterized by high blood pressure in arteries of the lungs, leading to symptoms such as shortness of breath and fatigue. Growing prevalence of PAH is one of the factors encouraging the governments to boost drug discovery and development. According to a data published by American Journal of Managed Care in March 2021, pulmonary arterial hypertension occurs in 32.5 per million population in the U.S. and Europe.
Governments often collaborate with pharmaceutical companies, research institutions, and healthcare organizations to provide financial support, regulatory guidance, and incentives for drug development in PAH. Funding initiatives, such as grants and subsidies, enable researchers to conduct preclinical and clinical trials, facilitating the exploration of novel therapies and the enhancement of existing ones. For instance, in September 2022, Eko received funding of around USD 2.7 million from NIH for development of advanced algorithms and integrated technologies to deal with pulmonary arterial hypertension.
Regulatory agencies, like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), work closely with developers to streamline approval processes for PAH drugs. Fast-track designations, orphan drug status, and priority review pathways are some mechanisms through which governments expedite the development and approval of treatments for rare diseases like PAH. For instance, in September 2024, Merck received FDA priority review status for its Sotatercept for the treatment of pulmonary arterial hypertension in adults.
Moreover, governments may establish patient registries and databases to collect real-world data on PAH, aiding in post-marketing surveillance and long-term efficacy assessments. Collaborative efforts between public and private sectors enhance the overall landscape of PAH drug development, ensuring that innovative therapies reach patients in a timely and safe manner. Such government support is essential to addressing the unmet medical needs of individuals affected by PAH and improving their quality of life.
Prostacyclin and prostacyclin analogs led the market and accounted for 47.2% of the global revenue in 2024.Prostacyclin is a potent vasodilator and one of the most effective drugs for the treatment of PAH. It is produced from arachidonic acid through the Cyclooxygenase (COX) pathway and is released by endothelial cells in pulmonary artery. Prostacyclin binds to the prostaglandin receptors to promote relaxation of smooth muscles and vasodilation through the activation of G protein and protein kinase. According to a study published by the researchers at the American College of Cardiology in October 2024, the oral prostacyclin receptor agonist selexipag has shown promising results for treatment of PAH. Currently, the group is working on investigating the efficacy of prostacyclin for pulmonary arterial hypertension.
SGC Stimulators are estimated to register fastest CAGR during the forecast period. Soluble Guanylate Cyclase (sGC) is a core enzyme in cardiovascular system. It is also the receptor for Nitric Oxide (NO). It has emerged as a therapeutic target in cardiopulmonary diseases, such as PAH, which is associated with impaired NO synthesis. It also results in endothelial dysfunction and inadequate stimulation of the NO-sGC-cGMP pathway. This hinders vasorelaxation and smooth muscle proliferation in PAH patients.
Branded segment accounted for the largest share of the pulmonary arterial hypertension market in 2024. Increasing number of product approvals, strong pipeline, and heavy investments by market players are responsible for largest share of branded segment. In addition, growing number of product launches are also expected to have positive impact on the segment growth during the forecast period. For instance, in June 2022, United Therapeutics Corporation received FDA approval for its Tyvaso DPI powder for the treatment of pulmonary arterial hypertension market.
Generic type segment is estimated to register fastest CAGR during the forecast period. Certain factors such as cost, patent expiry, and availability of generics is likely to boost the growth of generic segment by 2030. In September 2022, Lupin announced launch of generic Sildenafil for the treatment of pulmonary arterial hypertension in the U.S. marketplace.
By Route of administration, oral segment held the largest share in pulmonary arterial hypertension market of 60.0% in 2024. This is attributable to growing availability of oral formulations for PAH and patient preference for oral route of administration. Letairis, Opsumit, Adcirca, and Revatio are some examples of oral PAH drugs. In addition, increasing approvals for new oral formulations are also estimated to offer favorable opportunity for segment growth during the forecast period. For instance, in November 2024, Tenax Therapeutics, Inc. received FDA approval for its TNX-103 IND application. The company is investigating oral levosimendan for the treatment of pulmonary arterial hypertension.
The intravenous/ subcutaneous segment is anticipated to register the fastest growth over the forecast period. Intravenous drugs offer notable benefits in the treatment of Pulmonary Arterial Hypertension (PAH). Administered directly into the bloodstream, these drugs can rapidly achieve therapeutic levels, providing prompt relief of symptoms. Intravenous delivery ensures consistent absorption and bioavailability, crucial for managing the complex pathophysiology of PAH. Moreover, this method allows for precise dosage adjustments, optimizing therapeutic outcomes.
North America dominated the market and accounted for 32.1% share in 2024. Developed healthcare infrastructure in U.S. enabled access to advanced therapeutics which contributed to the growth of this region. Moreover, availability of reimbursement on PAH therapies supported the growth of North American PAH market. Growing awareness, high diagnosis rate and supportive government initiatives governed the growth of this region. Sedentary lifestyle habits such as smoking, alcohol and junk food are vital risk factors for development of PAH.
Asia Pacific is anticipated to witness significant growth in the pulmonary arterial hypertension market. Economic developments in countries such as India and China are expected to help market growth. High population and low per capita income led to rise in demand for affordable treatment options. MNCs are focused on investing in developing countries such as India and China. Thus, many partnerships and strategic alliances are being undertaken by organizations in this region. Further, rapid development in Asia Pacific region, high population, and improving healthcare systems are anticipated to aid in lucrative growth of the region. The Organization for Rare Diseases India (ORDI) serves as a prominent organization for all rare disease patients in India. The government has proposed substantial financial support, amounting to USD 0.18 million through the Rashtriya Arogaya Nidhi. This funding is intended for individuals needing one-time treatment under the Rare Diseases Policy 2020. Such initiative undertaken by India government are likely to play a major role in market growth.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the pulmonary arterial hypertension market
By Drug Class
By Type
By Route of Administration
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers